Ajanta Pharma Q4 Results: Net profit increased 66% year-on-year to Rs 230 million.

New Delhi-based Ajanta Pharma on Thursday reported a 66 per cent rise in consolidated net profit at Rs 230 crore in the March quarter, driven by robust sales in domestic and international markets. The pharma company had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal.

Ajanta Pharma said in a regulatory filing that its operating revenue stood at Rs 1,054 million in the fourth quarter of FY24, compared to Rs 882 million in the same period last year.

For the financial year ended March 31, 2024, the company recorded a consolidated net profit of Rs 816 crore as against Rs 588 crore in fiscal 2022-23.

Revenue from operations increased to Rs 4,209 crore in FY24 compared to Rs 3,743 crore in FY23.

The company said it distributed Rs 642 crore to shareholders in the form of dividends in FY24. The pharmaceutical company has generated a cash flow of Rs 812 crore and considering this financial position, the board has approved distribution of Rs 351 crore to shareholders in the form of share buyback. This share buyback includes purchase of 10,28,881 shares at a price of Rs 2,770 per share, equivalent to 0.82% of the total paid-up capital.

The company’s shares rose 0.68% to Rs 2,233.10 per share on BSE.